4 Biomedical Stocks Canaccord Loves

May 26, 2015

14

Cannacord recently attended the EuroPCR 2015 scientific sessions in Paris, and analysts followed up on the event by releasing a report this week on four of their top biotech stock picks. According to the report, the event provided updates that were “testament to our belief that the interventional cardiology arena will be one of the most dynamic in med-tech for years to come.”

Here’s a quick takeaway summary of what Cannacord saw at the conference.

TMVR Takes Center Stage

Analysts note that the sessions discussing transcatheter mitral valves (TMVR) were especially crowded. The unproven devices are still very early in their development, and many questions remain unanswered at this point. However, analysts explain that the need to find a less-invasive treatment for mitral regurgitation is “inarguable,” and some form of TMVR could eventually prove to be a viable solution.

TAVI Still Showing Potential

Despite the excitement surrounding TMVR, transcatheter aortic valve implantation (TAVI) still shows lots of promise. Both Edwards Lifesciences Corp (NYSE: EW) and Medtronic PLC (NYSE: MDT) have reported continuing success with SAPIEN 3 and Evolut R, respectively. Analysts do note growing concerns over seemingly manageable thrombus formation on some valves.

Analysts will be watching for important TAVI clinical data on the calendar in 2016 and predict “strong growth” in TAVI through 2020.